@article{TCR16172,
author = {Changmin Liu and Shaoshui Chen and Ping Wang and Dianzhong Geng and Weiming Zhang and Jing Yang and Judong Luo and Fangling Ning},
title = {Preliminary study of the treatment effect of apatinib mesylate upon malignant ascites and its safety},
journal = {Translational Cancer Research},
volume = {6},
number = {5},
year = {2017},
keywords = {},
abstract = {Background: This paper reports the effect of combining oral apatinib and abdominal cavity perfusion with cis-platinum for malignant ascites and its safety.
Methods: Seventeen malignant ascite patients were treated with oral apatinib (500 mg/d) and abdominal cavity perfusion of 60 mg/m2 cis-platinum (apatinib group), and 12 patients were treated with cis-platinum (60 mg/m2) only (control group). Twenty-one days was deemed as a cycle for both groups. Short-term treatment effects, quality of life (QOL), and toxicity were evaluated. Enzyme-linked immunosorbent assay (ELISA) was used to determine the vascular endothelial growth factor (VEGF) level in ascites.
Results: The response rates in apatinib and control groups were 70.6% and 33.3% (P},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/16172}
}